PET scanner


Group lead
Dr Laura Kenny

Related themes

Disease areas

What we do

We research novel positron emission tomography (PET) imaging methods for assessing cancer metabolism and response to treatment, as well as novel drugs for the treatment of cancer.  

Why it is important

New drugs are important in improving the outcome for cancer patients and better imaging will help us define which patients may benefit from targeted therapies, detect resistance at an early time-point and enable patients to receive effective treatments. 

How it can benefit patients

Through working as a clinician, we understand the problems that arise from current cancer treatments. The research we do directly involves patients, and we work closely with scientists to focus research that will have a meaningful impact for cancer patients. 

Summary of current research

  • [18F]GE226 – HERPET study: A new Affibody probe that will be studied in patients with breast cancer to determine if we can image the HER2 growth factor receptor non-invasively
  • INC280 study:  A commercial study of capmatinib in patients with advanced cancer
  • IPET study: Irosustat window study, response assessment using [18]FLT-PET
  • POPPET study: Study of [18F]FLT-PET and [18F]FDG-PET in high grade ductal carcinoma in situ
  • [18F]ICMT-11 as a marker of apoptosis in breast cancer patients undergoing neoadjuvant chemotherapy



  • AACR Young Investigator Award
  • McElwain Prize
  • ASCO Merit Award


For patient-related information please see:

PhD students

When we have funding for PhD studentships, we advertise them through central channels such as Find a PhD. Information is also available on the Surgery and Cancer study page. If no studentships are currently advertised, please get in touch with the group lead with proposed project titles to discuss further. 

Our researchers